Breaking News Instant updates and real-time market news.

TSLA

Tesla

$288.92

-11.81 (-3.93%)

06:59
10/25/18
10/25
06:59
10/25/18
06:59

Tesla results put 'extreme bear case to rest,' says Barclays

The cash generation and stronger margin performance in Tesla's Q3 "put the 'extreme' bear case to rest for a while but doesn't dispel the valuation debate," Barclays analyst Brian Johnson tells investors in a post-earnings research note titled "Extreme bear fears of distress prove misplaced." Further, the analyst feels that while Tesla's profit and improvement "was impressive," it comes after a "rich Model 3 mix" that's unlikely to be replicated. Tesla will soon be facing flat sequential revenue growth and by year-end 2019, slower year-over-year growth, says Johnson. The analyst keeps an Underweight rating on Tesla, but admits he does not have "near-term hopes" of seeing his $210 price target. However, he believes Tesla's "stabilizing growth" makes his "long-term valuation more realistic."

  • 29

    Oct

  • 13

    Dec

TSLA Tesla
$288.92

-11.81 (-3.93%)

10/24/18
10/24/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Tesla (TSLA) initiated with an Outperform at JMP Securities. 2. Comcast (CMCSA) resumed with a Buy at Deutsche Bank, reinstated with a Buy at Citi, and assumed with a Neutral at Guggenheim. 3. 2U (TWOU) initiated with a Buy at Needham. 4. Corbus Pharmaceuticals (CRBP) initiated with a Buy at B. Riley FBR. 5. Entasis Therapeutics (ETTX) initiated with a Buy at SunTrust. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
10/25/18
UBSW
10/25/18
NO CHANGE
Target $190
UBSW
Sell
Don't get used to Tesla's profitability, says UBS
In a post-earnings research note titled "Profitability at last, just don't get used to it," UBS analyst Colin Langan keeps a Sell rating on Tesla with a $190 price target following last night's Q3 results. Higher Model 3 pricing was likely the biggest driver of the margin beat in Q3, the analyst contends. He notes that Tesla's free cash flow of $900M came in above his $500M estimate due to lower capital expenditures, a higher than expected accrued liabilities benefit, and higher earnings. Langan, however, continues to expect Model 3 average selling prices to decline into Q4 and 2019 as Tesla begins delivering the new $46,000 mid-range model.
10/25/18
PIPR
10/25/18
NO CHANGE
Target $396
PIPR
Overweight
Piper boosts Tesla price target to $396 after 'milestone' quarter
Piper Jaffray analyst Alexander Potter raised his price target for Tesla to $396 from $389 following last night's Q3 results. Tesla reported a "milestone quarter," with margins, earnings, and cash flow easily beating expectations, Potter tells investors in a research note. While there is a still a lot of "hair" on this company, bears will struggle to poke holes in the results, Potter contends. He believes that with Tesla achieving high-volume production of Model 3 sedans, additional capital raises are probably not necessary. Tesla appears increasingly likely to achieve financial self-sufficiency, says Potter. The analyst reiterates an Overweight rating on Tesla shares, which are up 8%, or $22.60, to $311.10 in premarket trading.
10/25/18
JPMS
10/25/18
NO CHANGE
Target $225
JPMS
Underweight
Tesla price target raised to $225 from $195 at JPMorgan
JPMorgan analyst Ryan Brinkman raised his price target for Tesla to $225 from $195 citing the company's sooner than expected profit and cash generation. The analyst expects a "strong positive reaction" to Tesla's "materially" better than expected Q3 results last night He points out that revenue, gross margin, earnings, and, most importantly in his view, free cash flow all tracked better than was expected. Brinkman now expects Tesla's first full year of positive earnings to be in 2019 versus 2020 prior. The analyst, however, keeps an Underweight rating on the shares. He cites valuation for the rating and concern that the new stronger trajectory to earnings and cash "may prove less sustainable than the market is likely to presume."

TODAY'S FREE FLY STORIES

13:55
05/24/19
05/24
13:55
05/24/19
13:55
General news
NY Fed's Q2 GDP nowcast trimmed growth to 1.41% »

NY Fed's Q2 GDP…

INCY

Incyte

$81.34

0.84 (1.04%)

, NVS

Novartis

$88.05

3.59 (4.25%)

13:52
05/24/19
05/24
13:52
05/24/19
13:52
Hot Stocks
Incyte announces FDA approves Jakafi for acute GVHD »

Incyte Corporation…

INCY

Incyte

$81.34

0.84 (1.04%)

NVS

Novartis

$88.05

3.59 (4.25%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    May

  • 31

    May

  • 05

    Jun

  • 10

    Jun

  • 11

    Jun

  • 13

    Jun

  • 17

    Jun

AMRN

Amarin

$17.71

0.43 (2.49%)

13:50
05/24/19
05/24
13:50
05/24/19
13:50
Options
Amarin attracts call buyers in contracts that expire in one week »

Amarin attracts call…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DMRC

Digimarc

$62.52

-1.09 (-1.71%)

13:48
05/24/19
05/24
13:48
05/24/19
13:48
Recommendations
Digimarc analyst commentary  »

Digimarc price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    May

INCY

Incyte

$81.22

0.72 (0.89%)

13:39
05/24/19
05/24
13:39
05/24/19
13:39
Hot Stocks
FDA approves expanded indication for Incyte's Jakafi »

According to a post to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    May

  • 31

    May

  • 05

    Jun

  • 10

    Jun

  • 11

    Jun

  • 13

    Jun

  • 17

    Jun

MOMO

Momo

$25.94

-0.72 (-2.70%)

13:35
05/24/19
05/24
13:35
05/24/19
13:35
Options
Momo put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    May

  • 11

    Jun

ALPN

Alpine Immune Sciences

$5.27

-0.34 (-6.06%)

, ADAP

Adaptimmune

$3.62

-0.03 (-0.82%)

13:34
05/24/19
05/24
13:34
05/24/19
13:34
Recommendations
Alpine Immune Sciences, Adaptimmune, Gilead analyst commentary at Piper Jaffray »

Alpine Immune Sciences…

ALPN

Alpine Immune Sciences

$5.27

-0.34 (-6.06%)

ADAP

Adaptimmune

$3.62

-0.03 (-0.82%)

GILD

Gilead

$66.88

-0.27 (-0.40%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    May

  • 13

    Jun

  • 17

    Jun

ALPN

Alpine Immune Sciences

$5.27

-0.34 (-6.06%)

, GILD

Gilead

$66.91

-0.24 (-0.36%)

13:30
05/24/19
05/24
13:30
05/24/19
13:30
Hot Stocks
Alpine Immune Sciences reports notice of termination of license pact with Kite »

In a regulatory filing…

ALPN

Alpine Immune Sciences

$5.27

-0.34 (-6.06%)

GILD

Gilead

$66.91

-0.24 (-0.36%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    May

  • 13

    Jun

NVS

Novartis

$88.00

3.54 (4.19%)

, BIIB

Biogen

$228.00

-1.05 (-0.46%)

13:30
05/24/19
05/24
13:30
05/24/19
13:30
Hot Stocks
ICER says Zolgensma price falls within upper bound of benchmark range »

The Institute for…

NVS

Novartis

$88.00

3.54 (4.19%)

BIIB

Biogen

$228.00

-1.05 (-0.46%)

IONS

Ionis Pharmaceuticals

$65.44

-1.69 (-2.52%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    May

  • 31

    May

  • 05

    Jun

  • 06

    Jun

  • 17

    Jun

  • 18

    Jun

GOLD

Barrick Gold

$11.93

-0.03 (-0.25%)

, ABGLF

Acacia Mining

$0.00

(0.00%)

13:23
05/24/19
05/24
13:23
05/24/19
13:23
Periodicals
Barrick CEO tells Reuters Acacia bid reflects Tanzania risk »

Barrick Gold (GOLD) CEO…

GOLD

Barrick Gold

$11.93

-0.03 (-0.25%)

ABGLF

Acacia Mining

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

13:17
05/24/19
05/24
13:17
05/24/19
13:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

13:16
05/24/19
05/24
13:16
05/24/19
13:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CTSH

Cognizant

$61.83

0.75 (1.23%)

13:12
05/24/19
05/24
13:12
05/24/19
13:12
Hot Stocks
Cognizant CEO buys 19K shares of company stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Jun

  • 23

    Jun

NFLX

Netflix

$355.84

3.61 (1.02%)

, GOOG

Alphabet

$1,144.00

3.45 (0.30%)

13:08
05/24/19
05/24
13:08
05/24/19
13:08
Hot Stocks
Netflix to release 'Little Black Mirror' episodes on YouTube starting May 26 »

Netflix Latin America…

NFLX

Netflix

$355.84

3.61 (1.02%)

GOOG

Alphabet

$1,144.00

3.45 (0.30%)

GOOGL

Alphabet Class A

$1,148.10

3.22 (0.28%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Jun

  • 03

    Jun

  • 06

    Jun

  • 19

    Jun

  • 19

    Jun

  • 25

    Jun

  • 27

    Oct

13:07
05/24/19
05/24
13:07
05/24/19
13:07
General news
Baker-Hughes Rig Count N. Amer. data reported »

Week of 5/24 Baker-Hughes…

UAL

United Continental

$81.10

0.19 (0.23%)

, BA

Boeing

$356.58

6.01 (1.71%)

13:07
05/24/19
05/24
13:07
05/24/19
13:07
Periodicals
United extending Boeing 737 Max cancellations through August 3, CNBC reports »

United Airlines (UAL)…

UAL

United Continental

$81.10

0.19 (0.23%)

BA

Boeing

$356.58

6.01 (1.71%)

AAL

American Airlines

$29.41

-0.08 (-0.27%)

LUV

Southwest

$51.33

0.36 (0.71%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    May

  • 05

    Jun

  • 12

    Jun

  • 12

    Jun

  • 25

    Jul

  • 13

    Nov

BBY

Best Buy

$64.89

-0.9 (-1.37%)

, SSNLF

Samsung

$0.00

(0.00%)

13:04
05/24/19
05/24
13:04
05/24/19
13:04
Periodicals
Best Buy cancels preorders for Samsung's foldable phone, CNN reports »

Best Buy (BBY) is…

BBY

Best Buy

$64.89

-0.9 (-1.37%)

SSNLF

Samsung

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    May

  • 30

    May

  • 11

    Jun

BHGE

Baker Hughes

$22.28

-0.78 (-3.38%)

13:03
05/24/19
05/24
13:03
05/24/19
13:03
Hot Stocks
Baker Hughes reports U.S. rig count down 4 to 983 rigs »

Baker Hughes reports that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

V

Visa

$162.59

1.07 (0.66%)

13:02
05/24/19
05/24
13:02
05/24/19
13:02
Hot Stocks
Visa CFO Vasant Prabhu appointed company vice chairman »

Visa announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    May

  • 05

    Jun

EHC

Encompass Health

$59.22

-0.315 (-0.53%)

13:01
05/24/19
05/24
13:01
05/24/19
13:01
Hot Stocks
Encompass Health names Kim Sullivan chief human resources officer »

Encompass Health…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Jun

IONS

Ionis Pharmaceuticals

$67.35

0.215 (0.32%)

, BIIB

Biogen

$229.80

0.75 (0.33%)

13:01
05/24/19
05/24
13:01
05/24/19
13:01
Hot Stocks
Ionis, Biogen slip after FDA approves Novartis' Zolgensma for SMA treatment »

Shares of Ionis…

IONS

Ionis Pharmaceuticals

$67.35

0.215 (0.32%)

BIIB

Biogen

$229.80

0.75 (0.33%)

NVS

Novartis

$87.21

2.75 (3.26%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    May

  • 31

    May

  • 05

    Jun

  • 06

    Jun

  • 17

    Jun

  • 18

    Jun

XRT

S&P Retail Index SPDR

$41.58

-0.09 (-0.22%)

13:00
05/24/19
05/24
13:00
05/24/19
13:00
Options
Size four-way put spread in SPDR Retail Trust as shares extend losses »

Size four-way put spread…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RGNX

Regenxbio

$43.60

1.11 (2.61%)

, NVS

Novartis

$87.13

2.67 (3.16%)

12:53
05/24/19
05/24
12:53
05/24/19
12:53
Hot Stocks
Regenxbio up 6% after Novartis receives FDA approval for Zolgensma »

Regenxbio (RGNX) will…

RGNX

Regenxbio

$43.60

1.11 (2.61%)

NVS

Novartis

$87.13

2.67 (3.16%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    May

  • 31

    May

NVS

Novartis

$87.04

2.58 (3.05%)

12:47
05/24/19
05/24
12:47
05/24/19
12:47
Hot Stocks
Novartis says wholesale acquisition cost of Zolgensma $2.125M »

AveXis, a Novartis…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    May

TIVO

TiVo

$6.87

0.04 (0.59%)

12:45
05/24/19
05/24
12:45
05/24/19
12:45
Options
TiVo call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Jun

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.